Abstract
OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (χ1 = 4.30, p < .05) with 100% of risperidone subjects improving by more than 30% from baseline to endpoint, whereas only 77% of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Copyright 2007
| Original language | English |
|---|---|
| Pages (from-to) | 558-565 |
| Number of pages | 8 |
| Journal | Journal of the American Academy of Child and Adolescent Psychiatry |
| Volume | 46 |
| Issue number | 5 |
| DOIs | |
| State | Published - May 1 2007 |
| Externally published | Yes |
Fingerprint
Keywords
- Aggression
- Attention-deficit/hyperactivity disorder
- Augmentation
- Risperidone
ASJC Scopus subject areas
- Psychiatry and Mental health
- Developmental and Educational Psychology
Cite this
Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder : A placebo-controlled pilot study. / Armenteros, Jorge L.; Lewis, John E; Davalos, Marisabel.
In: Journal of the American Academy of Child and Adolescent Psychiatry, Vol. 46, No. 5, 01.05.2007, p. 558-565.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder
T2 - A placebo-controlled pilot study
AU - Armenteros, Jorge L.
AU - Lewis, John E
AU - Davalos, Marisabel
PY - 2007/5/1
Y1 - 2007/5/1
N2 - OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (χ1 = 4.30, p < .05) with 100% of risperidone subjects improving by more than 30% from baseline to endpoint, whereas only 77% of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Copyright 2007
AB - OBJECTIVE: To evaluate the effects of risperidone augmentation for treatment-resistant aggression in children with attention-deficit/hyperactivity disorder (ADHD). METHOD: Twenty-five children (ages 7-12 years) with attention-deficit/hyperactivity disorder (ADHD) and significant aggressive behaviors were randomized to risperidone or placebo for 4 weeks for this double-blind study. Subjects were already in treatment with a constant dose of psychostimulant medication. The primary efficacy measure was change from baseline in the Children's Aggression Scale-Parent (CAS-P) and -Teacher (CAS-T) total scores. RESULTS: The mean risperidone dose at endpoint was 1.08 mg/day. For the CAS-P total score, a significant difference was found (χ1 = 4.30, p < .05) with 100% of risperidone subjects improving by more than 30% from baseline to endpoint, whereas only 77% of the placebo group reported a similar response. No differences were found on the CAS-T total score. For the CAS-P and CAS-T, no significant interaction was found between treatment group and time. Rates of adverse events did not differ significantly between groups. CONCLUSIONS: Risperidone treatment appears to be well tolerated and modestly effective when used in combination with psychostimulants for treatment-resistant aggression in children with ADHD. Copyright 2007
KW - Aggression
KW - Attention-deficit/hyperactivity disorder
KW - Augmentation
KW - Risperidone
UR - http://www.scopus.com/inward/record.url?scp=34247370682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34247370682&partnerID=8YFLogxK
U2 - 10.1097/chi.0b013e3180323354
DO - 10.1097/chi.0b013e3180323354
M3 - Article
VL - 46
SP - 558
EP - 565
JO - Journal of the American Academy of Child and Adolescent Psychiatry
JF - Journal of the American Academy of Child and Adolescent Psychiatry
SN - 0890-8567
IS - 5
ER -